FDA Recall Announcement

Baxter Issues Updated Use Instructions for Volara Ventilator Circuits Following Serious Injury Reports

Baxter International has issued an Urgent Medical Device Correction for its Volara respiratory therapy system, specifically involving single-patient use circuits (Blue Ventilator Adaptor Module, Product Code M07937) used in conjunction with ventilators.

The U.S. Food and Drug Administration has classified this action as a Class I recall, the most serious type, indicating that continued use without adherence to updated instructions may cause serious injury or death.

Importantly, this is a field correction, not a product removal. Devices remain in use, but updated Instructions for Use (IFU) must be followed.

What Changed

Baxter updated use instructions for all affected Volara circuits after identifying risks associated with in-line use with ventilators in home care settings. The correction includes an updated IFU addendum, additional warnings for patient populations, reinforced monitoring requirements, and required training and acknowledgment by users.

Risk Overview

Baxter identified two primary risks when the Volara system is used in-line with a ventilator. The risks are oxygen desaturation (reduced oxygen levels) and barotrauma (lung injury from overexpansion).

These risks arise because the Volara system introduces additional flow and pressure, which may interfere with ventilator performance and therapy accuracy.

Reported Events

Seven serious injuries were reported between May 2022 and March 2026. No deaths were reported in this updated correction. Prior reporting for events in 2022 included one serious injury and two deaths.

Required Actions for Patients and Caregivers

Patients using the Volara system in-line with a ventilator should continue therapy as prescribed by their physician and carefully review the updated IFU addendum. Patients and caregivers should also monitor for signs of respiratory distress, including an increased breathing rate, wheezing, a bluish discoloration of the lips or nails, reduced oxygen saturation, or changes in alertness.

If symptoms occur, stop therapy immediately and seek medical attention if symptoms do not improve.

Additional Safeguards

Baxter is implementing direct communication with all affected users, access to 24/7 clinical support, in-home training by clinical patient trainers, and confirmation of understanding of updated instructions.  

Regulatory Insight (MDP Perspective)

This correction highlights several critical regulatory and quality system themes.

System Integration Risk

Combining devices (Volara + ventilator) introduces complex interactions not always fully predictable during initial design.

Importance of IFU Clarity

In home care environments, instructions must account for non-clinical users (patients/caregivers).

Post-Market Surveillance

This issue underscores how real-world use reveals risks that may not emerge during premarket evaluation.

Training as a Risk Control

The requirement for IFU acknowledgment that includes in-home training demonstrates that user behavior is a critical control point.

Bottom Line

The Volara correction is a strong example of how device performance, user interaction, and system integration must be continuously evaluated in real-world conditions. For manufacturers, this reinforces the need for robust risk management, clear labeling and instructions, and effective post-market monitoring.

Contact Information

U.S. customers with questions should contact Baxter at 800-397-9071 for clinical support.

Links

Read the FDA’s announcement here.